Ferozsons Laboratories Limited has the distinction of being one of the leading companies providing treatments for Hepatitis patients in Pakistan for over a decade. Our work in the field of hepatology has been pivotal in changing the treatment landscape, initially through the local production of interferons, which reduced treatment costs by half, and subsequently through the introduction of Direct Acting Antivirals (DAAs) under a special access program in partnership with Gilead Sciences Inc. USA. In 2014, Ferozsons Laboratories Limited launched Sovaldi® (Sofosbuvir), the first DAA agent for the treatment of Hepatitis C under a special patient access program designed for Pakistan. More than 70,000 patients benefitted from this program since then. We have continued to provide treatment for various liver complications including Hepatitis C as well as cirrhotic complications due to advanced liver disease over these years.

Ferozsons Laboratories Limited works hand in hand with healthcare providers and medical societies on a number of programs raising hepatic diseases particularly hepatitis awareness, and delivering education as well as facilitating screening activities.

Our works include regular continuing medical education (CME) events that bring together top experts from Pakistan and around the world to explore the latest advancements in the field of hepatology. Ferozsons has also designed awareness and educational outreach programs around hepatitis awareness and prevention by creating alliances with local NGO’s and educational institutions.